Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3085530 | 1.00 | HPGD (0.47) | HPGDEPHX1HSD17B10USP30GPR119 | |
| SCHEMBL13817502 | 0.80 | ALDH1A1 (0.39) | — | |
| SCHEMBL1827484 | 0.79 | HPGD (0.51) | HPGDEPHX1USP30GPR119RECQL | |
| SCHEMBL20096239 | 0.78 | CCR5 (0.39) | HPGD | |
| SCHEMBL7122083 | 0.78 | HSD17B10 (0.54) | HSD17B10USP30 | |
| SCHEMBL7129588 | 0.78 | HSD17B10 (0.54) | HSD17B10USP30 | |
| SCHEMBL7122088 | 0.78 | HSD17B10 (0.54) | HSD17B10USP30 | |
| SCHEMBL19026787 | 0.77 | GPR119 (0.52) | HPGDEPHX1USP30GPR119RECQL | |
| SCHEMBL4186514 | 0.77 | HPGD (0.57) | HPGDEPHX1USP30GPR119RECQL | |
| SCHEMBL16415863 | 0.77 | EPHX1 (0.51) | HPGDEPHX1USP30GPR119RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790884-B2 | Acylaminopiperidine compound | ASTELLAS PHARMA INC. (JP) | 2010-09-07 | — | — | US | disclosed |
| US-20090131666-A1 | ACYLAMINOPIPERIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-2000469-A9 | ACYLAMINOPIPERIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2009-03-25 | — | — | EP | disclosed |
| EP-2000469-A2 | ACYLAMINOPIPERIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2008-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131666-A1 | ACYLAMINOPIPERIDINE COMPOUND | CCR4, CCR1, CCR3 | HPGD 4038/4885EPHX1 4152/4885HSD17B10 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.